



08-29-02

Express Mail No.: EL 500 771 US

TECH CENTER 1600/2900

SEP 4 3 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Santoro et al.

Serial No.: 09/533,399

Group Art Unit: 1617

Filed: March 22, 2000

Examiner: Travers, R.

For: METHODS OF TREATING
INFLAMMATORY AND VIRAL
DISORDERS BY ADMINISTERING
CYCLOPENTENONE COMPOUNDS

Attorney Docket No.: 10167-004

**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT UNDER
37 C.F.R. § 1.56 and § 1.97**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the continuing duty of disclosure imposed by 37 CFR § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to Reference EF-FH listed on the attached revised form PTO 1449. Copy of Reference EF-FH are enclosed herewith.

Identification of the listed reference is not to be construed as an admission of Applicants or Attorneys for Applicants that such reference is available as "prior art" against the subject application.

08/30/2002 TL0011 00000014 161150 09533399


01 FC:126 100.00 CH

Applicants respectfully request that the Examiner review the foregoing reference and that the reference be made of record in the file history of the application.

Pursuant to 37 CFR § 1.97(c), since this Information Disclosure Statement is being filed after the mailing date of a first Office Action on the merits, but before the mailing of a final action, notice of allowance, or an action with otherwise closes prosecution, Applicants believe that the required fee for filing this Supplemental Information Disclosure Statement is \$180.00. Please charge the required fee for filing this Supplemental Information Disclosure Statement to Deposit Account No. 16-1150. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: August 27, 2002

 35,203
Anthony M. Insogna (Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090